236 related articles for article (PubMed ID: 32087718)
1. The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.
Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
BMC Psychiatry; 2020 Feb; 20(1):77. PubMed ID: 32087718
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.
Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
BMC Psychiatry; 2018 Nov; 18(1):365. PubMed ID: 30428862
[TBL] [Abstract][Full Text] [Related]
3. Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).
Oluboka O; Clerzius G; Janetzky W; Schöttle D; Therrien F; Wiedemann K; Roy MA
BMC Psychiatry; 2023 May; 23(1):383. PubMed ID: 37259053
[TBL] [Abstract][Full Text] [Related]
4. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.
Mustafa S; Bougie J; Miguelez M; Clerzius G; Rampakakis E; Proulx J; Malla A
BMC Psychiatry; 2019 Apr; 19(1):114. PubMed ID: 30991969
[TBL] [Abstract][Full Text] [Related]
5. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
6. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.
Peters-Strickland T; Zhao C; Perry PP; Eramo A; Salzman PM; McQuade RD; Johnson BR; Sanchez R
CNS Spectr; 2016 Dec; 21(6):460-465. PubMed ID: 27531181
[TBL] [Abstract][Full Text] [Related]
7. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
[TBL] [Abstract][Full Text] [Related]
8. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
9. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
10. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L
J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296
[TBL] [Abstract][Full Text] [Related]
11. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
[TBL] [Abstract][Full Text] [Related]
12. Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate.
Such P; Olivares JM; Arias L; Troels Berg M; Madera J
Neuropsychiatr Dis Treat; 2021; 17():1881-1892. PubMed ID: 34140772
[TBL] [Abstract][Full Text] [Related]
13. BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study).
Schöttle D; Janetzky W; Therrien F; Wiedemann K
BMC Psychiatry; 2023 Mar; 23(1):162. PubMed ID: 36918846
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
Potkin SG; Preda A
Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
[TBL] [Abstract][Full Text] [Related]
16. Initiation of aripiprazole once-monthly in patients with schizophrenia.
Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
[TBL] [Abstract][Full Text] [Related]
17. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
[TBL] [Abstract][Full Text] [Related]
18. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry PP; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Dec; 241():425-432. PubMed ID: 30145513
[TBL] [Abstract][Full Text] [Related]
19. Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study.
Pae CU; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS
Clin Psychopharmacol Neurosci; 2021 May; 19(2):233-242. PubMed ID: 33888652
[TBL] [Abstract][Full Text] [Related]
20. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
